174 related articles for article (PubMed ID: 31274526)
1. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.
Routt E; Ratner D
Dermatol Surg; 2020 Aug; 46(8):1109-1112. PubMed ID: 31274526
[No Abstract] [Full Text] [Related]
2. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.
Scalvenzi M; Villani A; Costa C; Cappello M
Dermatol Ther; 2019 Jul; 32(4):e12971. PubMed ID: 31124200
[No Abstract] [Full Text] [Related]
4. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.
Woltsche N; Pichler N; Wolf I; Di Meo N; Zalaudek I
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e144-e145. PubMed ID: 30472793
[No Abstract] [Full Text] [Related]
5. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
6. BCC and vismodegib: can we treat and remold at the same time?
Russo F; Mancini V; Trovato E; Fimiani M; Taddeucci P
G Ital Dermatol Venereol; 2020 Feb; 155(1):119-120. PubMed ID: 29781264
[No Abstract] [Full Text] [Related]
7. Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases.
Giuffrida R; Kashofer K; Dika E; Patrizi A; Baraldi C; Di Meo N; Zalaudek I
Eur J Cancer; 2018 Mar; 91():177-179. PubMed ID: 29373258
[No Abstract] [Full Text] [Related]
8. Hepatotoxicity Associated With Vismodegib: Could Dose Reduction Be an Effective Management?
de Perosanz-Lobo D; Burgos-Blasco P; Moreno-Arrones OM; Bea-Ardebol S
Dermatol Surg; 2021 Jul; 47(7):1006-1007. PubMed ID: 34167133
[No Abstract] [Full Text] [Related]
9. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
10. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
12. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
Yang X; Dinehart SM
JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
[No Abstract] [Full Text] [Related]
13. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.
Wong C; Poblete-Lopez C; Vidimos A
J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372
[No Abstract] [Full Text] [Related]
14. Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.
Maul LV; Kähler KC; Hauschild A
JAMA Dermatol; 2016 Dec; 152(12):1387-1388. PubMed ID: 26720040
[No Abstract] [Full Text] [Related]
15. Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.
Apalla Z; Spyridis I; Kyrgidis A; Lazaridou E; Kyriakou A; Fotiadou C; Pikou O; Sotiriou E; Vakirlis E; Papageorgiou C; Delli F; Moutsoudis A; Manoli SM; Ioannides D; Lallas A
J Am Acad Dermatol; 2021 Dec; 85(6):1589-1592. PubMed ID: 33253837
[No Abstract] [Full Text] [Related]
16. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.
Gualdi G; Moro R; Regina V; Caravello S; Monari P; Calzavara-Pinton PG
Br J Dermatol; 2019 Aug; 181(2):406-407. PubMed ID: 30737996
[No Abstract] [Full Text] [Related]
17. Reversible cutaneous side effects of vismodegib treatment.
Kwong B; Danial C; Liu A; Chun KA; Chang AL
Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
[No Abstract] [Full Text] [Related]
18. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
[No Abstract] [Full Text] [Related]
19. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients.
Girard E; Lacour A; Abi Rached H; Ramdane N; Templier C; Dziwniel V; Desmedt E; Le Rhun E; Mortier L
J Am Acad Dermatol; 2018 Jun; 78(6):1213-1216.e2. PubMed ID: 29203435
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
